In a sweeping address that capped one of the most transformative years in AATS history, President David Adams challenged members to embrace change and help cardiothoracic surgery make an even bigger impact on the world.
“Progress is never inevitable,” Dr. Adams said, warning that longstanding success can lead to complacency. “Progress is fueled by dissatisfaction, impatience and vision.”
Tirone E. David, MD, confronted the problem of achieving excellence in surgery in his inaugural David J. Sugarbaker, MD, Memorial Lecture. Dr. David summarized what he thought were the seven main components:
The Thoracic Mini Oral Competition opened with a paper on genetic mutations found in malignant pleural mesothelioma.
David S. Schrump, MD, presented a study that he and his colleagues performed to examine the ability of a human Double Minute-2 inhibitor (RG7388) to affect malignant pleural mesothelioma cells in vitro and in vivo.
Getting ahead of postoperative complications is a surgeon’s goal, and two papers offering insight on postop atrial fibrillation and infective endocarditis were shared at the “When Patients Fall Off the Pathway” session.
The use of intra-operative AF inducibility can be an effective screening tool to identify a population of patients at increased risk of developing postoperative AF, according to the results of a study performed by Terrence Pong, MD, of Stanford University and his colleagues. A focus of their study was to determine if intra-operative inducibility of AF can be used as a tool to guide preventative therapy in the post-operative period to reduce rates of AF occurence.
Although cryothermal energy has been used for surgical ablation for more than 30 years, there has been no prospective study to assess its safety and efficacy. Niv Ad, MD, from the University of Maryland and Washington Adventist Hospital, presented the latest information on the ICE-AFIB IDE trial, designed to bridge this evidence gap. The intent of the trial is to assess the safety and sustained effectiveness of cryothermal ablation as a standalone energy source for surgical atrial fibrillation (AF) ablation.
On Tuesday morning, Peter Zilla, MD, of the University of Cape Town, and R. Morton Bolman, MD, professor of surgery, division of cardiothoracic surgery, University of Vermont, will present papers abd moderate a panel “Cardiac Surgery Intersociety Alliance: Cardiac Surgery For The Forgotten Millions.”
The AATS 99th Annual Meeting showcases the myriad of advances and progress in cardiac surgery that improve and extend the lives of millions of patients. Despite the decades of impressive progress in developing treatments, techniques, and technology in cardiac surgical care, a large population of patients in need remain untreated. Access to lifesaving cardiac surgery is beyond the reach of millions in the developing world.
The TAVR vs SAVR competition continues, and James Edelman, MD, offered more data to consider.
Periprocedural complications may be associated with increased mortality and cost after transcatheter (TAVR) or surgical (SAVR) aortic valve replacement. However, it has hitherto been unknown whether the impact of such complications on outcomes differs by treatment strategy, according to James Edelman, MD, who presented a study of these factors based upon the results of the PARTNER 2A randomized trial.
The competition for the best congenital paper kicked off with an entry from Bartholomew V. Simon, MD.
Myocyte preservation during neonatal cardiac surgery with cardioplegia remains a challenge, partly due to immature mitochondria that are unable to meet increased metabolic demands, according to Dr. Simon. Within mitochondria, the enzyme ATP synthase can increase the efficiency of ATP production by organizing ATP synthase monomers into multimers. The mitochondrial membrane protein cyclophilin D (CyPD) inhibits multimer assembly, and therefore, ATP production during fetal and neonatal life.
Through strong partnerships with industry and organizational supporters, the AATS Foundation provides unique opportunities to enhance and develop cardiothoracic surgeons’ knowledge and skills.
Partners continue to collaborate with the Foundation in novel ways to support exciting new and existing programs that provide expanded education and training to the specialty. The AATS Foundation is grateful for corporate sponsors and organizational supporters who have given so generously over the years. Thank you to the following corporate and organizational lifetime donors below:
We are delighted to announce the appointment of twenty-six new members to the Editorial Board of the Journal of Thoracic and Cardiovascular Surgery for 2019. Editorial Board members contribute significantly to the success of the JTCVS by providing high-quality reviews, submitting insightful commentaries, and advising on journal policy and scope. The Editorial Board helps shape the tone and direction of the Journal through their careful assessments and unique contributions. The JTCVS would not continue to grow without their support, expertise, and ongoing dedication.